Marco Dutra Medeiros1, Edgar Mesquita2, Ana Luísa Papoila3, Victor Genro4, João Filipe Raposo5. 1. Portuguese Diabetes Association APDP, Lisbon, Portugal Department of Ophthalmology, Central Lisbon Hospital Center, Lisbon, Portugal NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal. 2. University of Minho, Braga, Portugal. 3. CEAUL, Lisbon, Portugal Statistics and Informatics Department, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal Epidemiology and Statistics Unit, Research Centre, Central Lisbon Hospital Center, Lisbon, Portugal. 4. Portuguese Diabetes Association APDP, Lisbon, Portugal. 5. Portuguese Diabetes Association APDP, Lisbon, Portugal Department of Public Health/CEDOC, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal.
Abstract
BACKGROUND/AIMS: In Portugal, so far, there is no study or even accurate data on the prevalence of diabetic retinopathy (DR), based on a large representative sample and on a long-term follow-up. The objective of our study was to determine the prevalence of DR based on a national screening community-based programme. METHODS: A 5-year retrospective analysis of the RETINODIAB screening programme results was implemented in Lisbon and Tagus Valley area between July 2009 and October 2014. We estimated the prevalence of retinopathy for all patients with type 2 diabetes and studied the association between known risk factors and retinopathy emergence at their first screening. RESULTS: Throughout this period, from a total of 103 102 DR readable screening examinations, 52 739 corresponded to patients who attended RETINODIAB screening at entry. Globally, DR was detected in 8584 patients (16.3%). Of these, 5484 patients (10.4%) had mild non-proliferative (NP) DR, 1457 patients (2.8%) had moderate NPDR and 672 (1.3%) had severe NPDR. Finally, 971 patients (1.8%) had proliferative DR requiring urgent referral to an ophthalmologist. The presence of any DR, non-referable DR or referable DR was strongly associated with increasing duration of diabetes and earlier age at diagnosis. CONCLUSIONS: The prevalence rate of DR in our study (16.3%) was slightly lower than other published international data. The RETINODIAB network proved to be an effective screening programme as it improved DR screening in Lisbon and Tagus Valley surrounding area. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND/AIMS: In Portugal, so far, there is no study or even accurate data on the prevalence of diabetic retinopathy (DR), based on a large representative sample and on a long-term follow-up. The objective of our study was to determine the prevalence of DR based on a national screening community-based programme. METHODS: A 5-year retrospective analysis of the RETINODIAB screening programme results was implemented in Lisbon and Tagus Valley area between July 2009 and October 2014. We estimated the prevalence of retinopathy for all patients with type 2 diabetes and studied the association between known risk factors and retinopathy emergence at their first screening. RESULTS: Throughout this period, from a total of 103 102 DR readable screening examinations, 52 739 corresponded to patients who attended RETINODIAB screening at entry. Globally, DR was detected in 8584 patients (16.3%). Of these, 5484 patients (10.4%) had mild non-proliferative (NP) DR, 1457 patients (2.8%) had moderate NPDR and 672 (1.3%) had severe NPDR. Finally, 971 patients (1.8%) had proliferative DR requiring urgent referral to an ophthalmologist. The presence of any DR, non-referable DR or referable DR was strongly associated with increasing duration of diabetes and earlier age at diagnosis. CONCLUSIONS: The prevalence rate of DR in our study (16.3%) was slightly lower than other published international data. The RETINODIAB network proved to be an effective screening programme as it improved DR screening in Lisbon and Tagus Valley surrounding area. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Einas S Elwali; Ahmed O Almobarak; Mona A Hassan; Amir A Mahmooud; Heitham Awadalla; Mohamed H Ahmed Journal: Int J Ophthalmol Date: 2017-06-18 Impact factor: 1.779
Authors: Asamere Tsegaw; Shitaye Alemu; Abere Dessie; Christopher C Patterson; Eldryd H O Parry; David I W Phillips; Elisabeth R Trimble Journal: J Ophthalmol Date: 2021-03-31 Impact factor: 1.909
Authors: Wojciech Matuszewski; Angelika Baranowska-Jurkun; Magdalena M Stefanowicz-Rutkowska; Robert Modzelewski; Janusz Pieczyński; Elżbieta Bandurska-Stankiewicz Journal: Medicina (Kaunas) Date: 2020-04-06 Impact factor: 2.430
Authors: Rafael Rodriguez-Acuña; Eduardo Mayoral; Manuel Aguilar-Diosdado; Reyes Rave; Beatriz Oyarzabal; Carmen Lama; Ana Carriazo; Maria Asuncion Martinez-Brocca Journal: BMJ Open Diabetes Res Care Date: 2020-10
Authors: Andreia Marisa Penso Pereira; Raul Manuel da Silva Laureano; Fernando Buarque de Lima Neto Journal: BMC Health Serv Res Date: 2021-07-30 Impact factor: 2.655